human
|
TDLo
|
oral
|
1410mg/kg/11W (1410mg/kg)
|
sense organs and special senses: visual field changes: eye
|
New Zealand Medical Journal. Vol. 111, Pg. 428, 1998.
|
mammal (species unspecified)
|
LD50
|
intravenous
|
350mg/kg (350mg/kg)
|
lungs, thorax, or respiration: other changes
|
Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 63(3), Pg. 114S, 1967.
|
mammal (species unspecified)
|
LD50
|
subcutaneous
|
890mg/kg (890mg/kg)
|
lungs, thorax, or respiration: other changes
|
Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 63(3), Pg. 114S, 1967.
|
man
|
TDLo
|
oral
|
332mg/kg/31D- (332mg/kg)
|
lungs, thorax, or respiration: "fibrosis, focal (pneumoconiosis)"
blood: eosinophilia
|
Journal of Allergy and Clinical Immunology. Vol. 100, Pg. 712, 1997.
|
man
|
TDLo
|
oral
|
600mg/kg (600mg/kg)
|
peripheral nerve and sensation: structural change in nerve or sheath
behavioral: changes in motor activity (specific assay)
kidney, ureter, and bladder: other changes in urine composition
|
British Medical Journal. Vol. 2, Pg. 1105, 1976.
|
man
|
TDLo
|
oral
|
1200mg/kg (1200mg/kg)
|
skin and appendages (skin): "dermatitis, other: after systemic exposure"
|
British Medical Journal. Vol. 2, Pg. 1105, 1976.
|
mouse
|
LD50
|
intraperitoneal
|
1075mg/kg (1075mg/kg)
|
behavioral: convulsions or effect on seizure threshold
|
Dissertationes Pharmaceuticae et Pharmacologicae. Vol. 23, Pg. 463, 1971.
|
mouse
|
LD50
|
intravenous
|
240mg/kg (240mg/kg)
|
behavioral: convulsions or effect on seizure threshold
|
Dissertationes Pharmaceuticae et Pharmacologicae. Vol. 23, Pg. 463, 1971.
|
mouse
|
LD50
|
oral
|
8700mg/kg (8700mg/kg)
|
behavioral: convulsions or effect on seizure threshold
|
Dissertationes Pharmaceuticae et Pharmacologicae. Vol. 23, Pg. 463, 1971.
|
rat
|
LD50
|
oral
|
998mg/kg (998mg/kg)
|
|
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 9, Pg. 759, 1967.
|
women
|
TDLo
|
oral
|
900mg/kg/60D- (900mg/kg)
|
liver: "jaundice, cholestatic"
|
British Medical Journal. Vol. 292, Pg. 866, 1986.
|